Skip to main content

Mark Bloomfield, Martin Rosenberg, Bruker Daltonik, German Collection of Microorganisms and Cell Cultures, PerkinElmer, Sigma-Aldrich, Rubicon, Ciphergen, Cepheid, Solexa

People

Mark Bloomfield joined Applied Biosystems as vice president of sales for molecular biology in Europe in November 2005, ABI said last week.

Bloomfield most recently was director of European commercial operations for the Scientific Instruments division of Thermo Electron. He has also served as aftermarket sales and sales development manager with Agilent Technologies Europe, and European business development manager for mass spectrometry and gas phase chromatography with Hewlett-Packard.


The National Institute of Allergy and Infectious Diseases last week appointed Martin Rosenberg to its principal advisory board.

Rosenberg is chief scientific officer of Promega. He is a director at Promega, Cubist Pharmaceuticals, Medical College of Wisconsin Research Foundation, Nereus Pharmaceuticals, Anacor Pharmaceuticals, and Scarab Genomics.

 

BioCommerce Briefs

German Group to Use Bruker BioTyper System for Protein Profiling

Bruker Daltonik and the German Collection of Microorganisms and Cell Cultures (DSMZ) will together identify and classify microorganisms from MALDI-TOF peptide and protein profiles, Bruker and DSMZ said this week.

The DSMZ will use Bruker's CLINPROT BioTyper system to generate protein profiles and analyze data.

As part of the collaboration, Bruker and DSMZ will generate a database including microorganism species and strains in application areas such as microbiological classification; clinical and diagnostic infectious disease research; and environmental analysis, food safety, and water quality.

Financial terms were not disclosed.

Separately, Bruker AXS Microanalysis, a division of Bruker BioSciences, will launch its Quantax Quad energy-dispersive spectroscopy system during Pittcon next month, the company said last week. The EDS system allows X-ray microanalysis on electron microscopes.

Pittcon will be held in Orlando, Fla., beginning on March 13.


Expanding in China, PerkinElmer Opens New Tech Center in Shanghai; Will Be New China HQ

PerkinElmer said this week that it has opened a new technology center in Shanghai, China, and that it will consolidate into it three existing facilities in that city.

The new center, which PerkinElmer said "allows for easy expansion," aims to bring together PerkinElmer's sales, service, customer care, and technology-support functions, and will be the company's regional headquarters for greater China.

The new center is located at Zhangjiang Bio-Pharma Park in Pudong New Territory.

PerkinElmer opened a subsidiary in China in 2003 to provide sales and service for its life and analytical sciences products. That space, which is located in the Shanghai WaiGaoQiao Free Trade Zone, was to employ approximately 100 sales and service staffers, the company said at the time.

It was not immediately clear if this space is one of the three the company plans to consolidate into the new technology center.


Sigma-Aldrich to Offer Rubicon's Genome Amplification Kits

Sigma-Aldrich said last week that it had signed a licensing deal allowing it to offer Rubicon Genomics' GenomePlex Whole Genome Amplification kits to service providers.

Rubicon Genomics will retain all rights to the kits for molecular diagnostics, and will continue its existing service business, Sigma-Aldrich said.

Additional terms of the arrangement were not disclosed.


Ciphergen Q4 Revenue Slides 35 Percent

Ciphergen last week reported that its fourth-quarter sales fell 35 percent to $6.6 million from $10.1 million during the year-ago period, as net income fell into the red.

Research and development costs fell to $3 million from $3.7 million a year ago.

Ciphergen reported a net loss of $9.2 million, or $0.26 per share, versus a net income of $10.3 million, or $0.35, in the fourth quarter of 2004. The company said the results included a $2.5-million non-cash charge for the impairment of goodwill.

As of Dec. 31, the company had $25.7 million in cash and cash equivalents.


Cepheid to Supply Anthrax Detection Platform to Two Biothreat Agenices

The State Regional Hazmat Response Team of Oakland, Mich., and the City and County of Honolulu Bio-Weapon Illness Prevention Program and EMS Medical Strike Team have each agreed to use Cepheid's GeneXpert real-time PCR platform for mobile anthrax detection, the company said last week.

Financial details were not disclosed.

Cepheid's shares rose 9 percent to close at $10.37 on Thursday, the day the announcement was made.


Solexa Shares Move to Nasdaq National Market

Nasdaq moved Solexa's exchange listing from the Capital Market to the National Market, Solexa said this week.

Solexa's shares began trading on the Nasdaq National Market on Wed., Feb. 22. Solexa's stock symbol will remain SLXA.

The Nasdaq Capital Market was formerly known as the Nasdaq SmallCap Market.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.